Canaccord lowered the firm’s price target on Clover Health (CLOV) to $4.10 from $4.50 and keeps a Buy rating on the shares. The firm said they reported solid Q2 results however the insurance benefit expense ration came in higher than expected which created some concern.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLOV: